Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.

Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn PA, Howard SJ, Hope WW.

Antimicrob Agents Chemother. 2013 Jan;57(1):281-8. doi: 10.1128/AAC.01387-12. Epub 2012 Oct 31.

2.

Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.

Warn PA, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J, Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK Jr, Hope WW.

Antimicrob Agents Chemother. 2012 Feb;56(2):708-14. doi: 10.1128/AAC.05826-11. Epub 2011 Nov 28.

3.

Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.

Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W.

Antimicrob Agents Chemother. 2012 May;56(5):2435-42. doi: 10.1128/AAC.06369-11. Epub 2012 Feb 21.

4.

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J.

Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. Epub 2007 Dec 10.

5.

Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW.

Antimicrob Agents Chemother. 2011 Oct;55(10):4880-7. doi: 10.1128/AAC.00621-11. Epub 2011 Aug 1.

6.

Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis.

Mochizuki K, Suemori S, Udo K, Komori S, Ohkusu K, Yamada N, Ogura S.

J Ocul Pharmacol Ther. 2011 Oct;27(5):531-3. doi: 10.1089/jop.2011.0026. Epub 2011 Jul 13.

PMID:
21751880
7.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Lepak AJ, Marchillo K, VanHecker J, Diekema D, Andes DR.

Antimicrob Agents Chemother. 2013 Nov;57(11):5642-8. doi: 10.1128/AAC.01354-13. Epub 2013 Sep 3.

8.

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Groll AH, Mickiene D, Petraitiene R, Petraitis V, Lyman CA, Bacher JS, Piscitelli SC, Walsh TJ.

Antimicrob Agents Chemother. 2001 Oct;45(10):2845-55.

9.

In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.

Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J.

Antimicrob Agents Chemother. 2008 Oct;52(10):3497-503. doi: 10.1128/AAC.00478-08. Epub 2008 Jul 14.

11.

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2497-506. doi: 10.1128/AAC.01584-09. Epub 2010 Apr 12.

12.

Echinocandin antifungal drugs in fungal infections: a comparison.

Chen SC, Slavin MA, Sorrell TC.

Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000. Review. Erratum in: Drugs. 2011 Jan 22;71(2):253.

PMID:
21175238
13.

Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.

Liu P.

Antimicrob Agents Chemother. 2013 Jan;57(1):466-74. doi: 10.1128/AAC.01473-12. Epub 2012 Nov 5.

14.

Management of endogenous fungal endophthalmitis with voriconazole and caspofungin.

Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG.

Am J Ophthalmol. 2005 Jan;139(1):135-40.

PMID:
15652837
15.

Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.

Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW.

Antimicrob Agents Chemother. 2011 Jul;55(7):3075-83. doi: 10.1128/AAC.01686-10. Epub 2011 Apr 18.

16.

Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits.

Petraitiene R, Petraitis V, Kelaher AM, Sarafandi AA, Mickiene D, Groll AH, Sein T, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2005 May;49(5):2084-92.

17.

Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.

Andes DR, Reynolds DK, Van Wart SA, Lepak AJ, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2013 Nov;57(11):5714-6. doi: 10.1128/AAC.01057-13. Epub 2013 Aug 19.

18.

Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.

Petraitiene R, Petraitis V, Groll AH, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 1999 Sep;43(9):2148-55.

19.

Pharmacokinetics and safety of intravitreal caspofungin.

Shen YC, Liang CY, Wang CY, Lin KH, Hsu MY, Yuen HL, Wei LC.

Antimicrob Agents Chemother. 2014 Dec;58(12):7234-9. doi: 10.1128/AAC.03324-14. Epub 2014 Sep 22.

20.

Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

Gauthier GM, Nork TM, Prince R, Andes D.

Clin Infect Dis. 2005 Aug 1;41(3):e27-8. Epub 2005 Jun 28.

Items per page

Supplemental Content

Write to the Help Desk